HFM
NWBO

Hartford Financial Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Hartford Financial Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,000
Closed -$2K – 339
2016
Q3 		$2K Buy
+4,000
New +$1.83K ﹤0.01% 309

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Hartford Financial Management's NWBO Position: Q4 2016 in Review

Hartford Financial Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 4,000 shares — an estimated $2K sold.

Hartford Financial Management first reported a position in NWBO in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Hartford Financial Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Hartford Financial Management sold 4,000 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $2K.
  • Hartford Financial Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2016 and held it in 1 quarter.
  • Hartford Financial Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $2K in Q3 2016.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Hartford Financial Management's 13F filing for Q4 2016, filed 13 Feb 2017.